title: GRP78 and α2-macroglobulin are new promising targets for metastatic castrate-resistant prostate cancer treatment.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, NYU Lutheran Medical Center, 150 55th Street, Brooklyn, NY, 11220, USA. pvlachostergios@lmcmc.com.
authors.forename: P J
authors.initials: PJ
authors.lastname: Vlachostergios
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, NYU Lutheran Medical Center, 150 55th Street, Brooklyn, NY, 11220, USA.
authors.forename: R L
authors.initials: RL
authors.lastname: Balmiki
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, NYU Lutheran Medical Center, 150 55th Street, Brooklyn, NY, 11220, USA.
authors.forename: R
authors.initials: R
authors.lastname: Daya
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000556:secondary*; D000091342:Endoplasmic Reticulum Chaperone BiP; D006801:Humans; D008297:Male; D010012:Osteogenesis; D010455:Peptides / Q000737:chemistry*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000378:metabolism*
chemical_list: D000091342:Endoplasmic Reticulum Chaperone BiP; C000717247:HSPA5 protein, human; D010455:Peptides